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We report the clinical course of photodynamic therapy (PDT) in a patient with drusenoid pigment epithelium 
detachment (PED). A patient with drusenoid PED underwent PDT follow-up was carried out at one week, 
one month, three months, six months and one year after treatment. Fundus exam, optical coherence 
tomography (OCT) and fluorescein angiography were performed. After the PDT, drusen and PED were 
gradually diminished over one year. However, pure serous PED eventually developed at the same location  
of the drusenoid PED. The results of the PDT, on drusenoid PED, were initially effective, but not completely 
successful. Therefore, PDT may be considered as an alternative treatment option for drusenoid PED.
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A variety of different types of pigment epithelium 
detachment (PED) have been identified in the medical 
literature. These types of PED can be classified as 
fibrovascular PED, serous detachment of RPE, hemorrhagic 
detachment of RPE and drusenoid RPE detachment.
1 
Verteporfin photodynamic therapy (PDT) has been used to 
safely reduce the risk of loss of vision in patients with 
choroidal neovascularization (CNV) in age-related macular 
degeneration.
2 We performed PDT on a patient with drusenoid 
PED and here report the clinical course.
Case Report
A 68-year-old man presented with decreased visual acuity 
in his left eye for several months. His corrected vision in the 
left eye was 20/40. There was no abnormality observed in 
the anterior segment. On fundus examination of the left eye, 
one disk diameter sized PED, with diffuse coalesced soft 
drusen was noted at the macula. At the first examination, 
fluorescein angiography revealed delayed, regular hyperfluore- 
scence without leakage and the OCT showed multiple 
pigment epithelium detachments. There was no evidence of 
CNV (Fig. 1A, B, C). PDT was performed at the PED site 
and around 1,000 µm
2. Fifteen days after PDT, the corrected 
vision for the left eye was 20/40. On the fundus examination, 
there was no interval change (Fig. 2A). Five months after 
PDT, the fundus examination showed a decreased size of the 
soft drusen (Fig. 2B). Ten months after PDT, the corrected 
vision of the left eye was improved to 20/25. On fundus 
examination and OCT, the number of soft drusen was 
markedly decreased (Fig. 2C). ICG showed that the drusenoid 
PED diminished in size (Fig. 1D, E, F). 
Discussion
Drusenoid PED has been distinguished from other types of 
injury by its better prognosis. This avascular PED typically 
develops slowly and causes minimal complaints of blurred 
vision. The natural history usually follows a progression to 
persistent drusenoid RPE detachment, geographic atrophy and 
neovascularisation.
3 The effect of PDT on drusenoid PED has 
not been confirmed, but the effect of a grid laser on drusen 
has been reported.
4 
The effects of PDT can be divided into the photochemical 
effect of verteporfin and the effect of the 689 nm nonthermal 
laser itself. As previously reported, vertiporfin has a very 
broad absorption spectrum, but only the far-red peak at 
688-691 nm is typically used in clinical practice. A beam of 
red laser light (689 nm diode laser) is applied to the retina 
via a slit lamp irradiating a spot of about 1 mm in diameter, 
with light intensity of 600 mW/cm
2, for 83 seconds, resulting 
in a total radiant exposure of 50 J/ cm.
2,5 Closure of abnormal 
(leaking) blood vessels occurs for approximately 6-12 weeks 
in most patients.
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Fig. 1. (A, B, C) Fundus photography and optical coherence tomography (OCT) at the first examination showed multiple pigment 
epithelium detachments. Fluorescein angiography revealed delayed, regular hyperfluorescence without leakage. There was no evidence
of choroidal neovascularization (CNV). (D, E, F) Ten months after photodynamic therapy (PDT), fundus photography, OCT and ICG 
showed that the drusenoid PED diminished in size. 
Fig. 2. (A) Fifteen days after PDT, there was no interval change, on the fundus examination. (B) Five months after PDT, the fundus
examination showed a decreased size of the soft drusen. (C) Ten months after PDT, the corrected vision of the left eye was improved
to 20/25. On fundus examination, the number of soft drusen was markedly decreased.
accelerate their removal by phagocytes, and that RPE 
proliferation induced by laser photocoagulation might reduce 
the amount of debris per cell and enhance the phagocytic 
capacity of the RPE.
6 Indirect effects of the laser may alter 
the characteristics of the lipids which cause Bruch’s 
membrane impairment, so that the soft drusen material 
escapes.
7 
In our case, PDT was effective for reducing the drusenoid 
PED. The effect was observed ten months after the PDT we 
thought the effect was caused by the laser, not the 
verteporfin. The efficacy of 689 nm diode laser on drusenoid 
PED has not been reported; the long term efficacy of the 
conventional PDT treatment is not known. Further studies are 
therefore warranted.
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